Suppr超能文献

甲状腺非霍奇金淋巴瘤:对1973年至1992年在诺丁汉郡确诊的所有患者的回顾性研究。

Non-Hodgkin's lymphoma of the thyroid: a retrospective review of all patients diagnosed in Nottinghamshire from 1973 to 1992.

作者信息

Pledge S, Bessell E M, Leach I H, Pegg C A, Jenkins D, Dowling F, Moloney A

机构信息

City Hospital NHS Trust, Nottingham, UK.

出版信息

Clin Oncol (R Coll Radiol). 1996;8(6):371-5. doi: 10.1016/s0936-6555(96)80082-3.

Abstract

The pathological and clinical features were reviewed of all primary non-Hodgkin's lymphomas (NHL) of the thyroid gland diagnosed between 1973 and 1992 in the population (1.1 million) served by the Nottingham and North Nottinghamshire Health Authorities. Of the 43 patients with histologically proven NHL, three had low grade mucosa associated lymphoid tissue (MALT) lymphomas (Stage IEA, 2; Stage IIEA, 1), 35 had intermediate or high grade lymphomas, Stage IEA or IIEA (intermediate MALT, 2; high grade MALT, 14; B-cell diffuse centroblastic, 17; anaplastic large cell (Ki-1) of null cell type, 1; high grade unclassifiable, 1), and one had unclassifiable NHL Stage IIEA. One patient had Stage IIIEA disease (high grade MALT) and three had stage IVA disease (high grade MALT, 2; B-cell diffuse centroblastic, 1). The median age was 68 years (range 45-86) with a female: male ratio of 6:1. For the 35 patients with intermediate or high grade thyroid NHL (Stages IEA and IIEA) the 5- and 10-year cause specific survival was 60%. The 21 patients treated between 1985 and 1992 initially with chemotherapy (except stage IEA (< 5 cm diameter) had a 5-year cause specific survival of 69% (95% CI 48-90) compared with 46% (95% CI 19-73) for the 14 patients treated between 1973 and 1984 with initial radiotherapy (Chi 2 = 1.62). The survival of those patients with intermediate or high grade MALT lymphomas was not significantly greater than of those patients with B-cell diffuse centroblastic NHL.

摘要

回顾了1973年至1992年间在诺丁汉和北诺丁汉郡卫生当局服务的人群(110万)中诊断出的所有原发性甲状腺非霍奇金淋巴瘤(NHL)的病理和临床特征。在43例经组织学证实为NHL的患者中,3例为低度黏膜相关淋巴组织(MALT)淋巴瘤(IEA期,2例;IIEA期,1例),35例为中度或高度淋巴瘤,IEA期或IIEA期(中度MALT,2例;高度MALT,14例;B细胞弥漫性中心母细胞性,17例;空细胞型间变性大细胞(Ki-1),1例;高度不可分类,1例),1例为不可分类的NHL IIEA期。1例患者为IIIEA期疾病(高度MALT),3例为IVA期疾病(高度MALT,2例;B细胞弥漫性中心母细胞性,1例)。中位年龄为68岁(范围45-86岁),女性与男性比例为6:1。对于35例中度或高度甲状腺NHL(IEA期和IIEA期)患者,5年和10年病因特异性生存率为60%。1985年至1992年最初接受化疗的21例患者(直径<5 cm的IEA期除外)5年病因特异性生存率为69%(95%可信区间48-90),而1973年至1984年最初接受放疗的14例患者为46%(95%可信区间19-73)(χ2 = 1.62)。中度或高度MALT淋巴瘤患者的生存率并不显著高于B细胞弥漫性中心母细胞性NHL患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验